fluorouracil has been researched along with Leukemia, Myeloid in 27 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, we developed an individualised fluorouracil, epirubicin, cyclophosphamide (FEC) regimen to improve outcomes in patients with high-risk early breast cancer." | 9.09 | Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. ( Anker, G; Bengtsson, NO; Bergh, J; Blomqvist, C; Erikstein, B; Holte, H; Kellokumpu-Lehtinen, P; Lidbrink, E; Lindman, H; Ljungman, P; Malmström, P; Nilsson, J; Ottosson, S; Salminen, E; Söderlund, G; Wiklund, T; Wilking, N; Wist, E, 2000) |
| "The purpose of this study was to evaluate incidence and risk factors of secondary leukemia after adjuvant epirubicin-based chemotherapy in breast cancer patients." | 8.82 | Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. ( Bonneterre, J; Campone, M; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P, 2005) |
| "This study retrospectively evaluates the occurrence of second hematological and solid malignancies in the context of a prospective multicenter phase III trial comparing epirubicin-cyclophosphamide at intermediate doses (EC), or at full doses (HEC), with classical cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 777 patients with early breast cancer." | 7.72 | Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer ( Accettura, C; Bernard-Marty, C; Cardoso, F; Di Leo, A; Kleiber, K; Larsimont, D; Lobelle, JP; Mano, M; Munoz-Bermeo, R; Paesmans, M; Piccart, MJ; Richard, T, 2003) |
| " Therefore, we developed an individualised fluorouracil, epirubicin, cyclophosphamide (FEC) regimen to improve outcomes in patients with high-risk early breast cancer." | 5.09 | Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. ( Anker, G; Bengtsson, NO; Bergh, J; Blomqvist, C; Erikstein, B; Holte, H; Kellokumpu-Lehtinen, P; Lidbrink, E; Lindman, H; Ljungman, P; Malmström, P; Nilsson, J; Ottosson, S; Salminen, E; Söderlund, G; Wiklund, T; Wilking, N; Wist, E, 2000) |
| "The purpose of this study was to evaluate incidence and risk factors of secondary leukemia after adjuvant epirubicin-based chemotherapy in breast cancer patients." | 4.82 | Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. ( Bonneterre, J; Campone, M; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P, 2005) |
| "This study retrospectively evaluates the occurrence of second hematological and solid malignancies in the context of a prospective multicenter phase III trial comparing epirubicin-cyclophosphamide at intermediate doses (EC), or at full doses (HEC), with classical cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 777 patients with early breast cancer." | 3.72 | Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer ( Accettura, C; Bernard-Marty, C; Cardoso, F; Di Leo, A; Kleiber, K; Larsimont, D; Lobelle, JP; Mano, M; Munoz-Bermeo, R; Paesmans, M; Piccart, MJ; Richard, T, 2003) |
| "Cytogenetic abnormalities were not found in the stem cell harvests of these patients by metaphase analysis or by fluorescence in situ hybridization (FISH)." | 1.31 | Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer. ( de Castro, K; Griffin, M; Hesdorffer, C; Lin, N; Murty, VV; Nichols, G; Oratzi, A; Troxel, A; Vahdat, L; Wei, LX, 2002) |
| "Thirteen cases of acute nonlymphocytic leukemia occurred among 5455 patients, as compared to 0." | 1.26 | Acute leukemia after alkylating-agent therapy of ovarian cancer. ( Fraumeni, JF; Hoover, R; Reimer, RR; Young, RC, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (40.74) | 18.7374 |
| 1990's | 7 (25.93) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 1 (3.70) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Pich, O | 1 |
| Cortes-Bullich, A | 1 |
| Muiños, F | 1 |
| Pratcorona, M | 1 |
| Gonzalez-Perez, A | 1 |
| Lopez-Bigas, N | 1 |
| Willems, L | 1 |
| Suarez, F | 1 |
| Messas, E | 1 |
| Baubion, N | 1 |
| Decaudin, D | 1 |
| Fourquet, A | 1 |
| Ghez, D | 1 |
| Delarue, R | 1 |
| Hermine, O | 1 |
| Buzyn, A | 1 |
| Varet, B | 1 |
| Rubio, MT | 1 |
| Nichols, G | 1 |
| de Castro, K | 1 |
| Wei, LX | 1 |
| Griffin, M | 1 |
| Lin, N | 1 |
| Oratzi, A | 1 |
| Murty, VV | 1 |
| Troxel, A | 1 |
| Vahdat, L | 1 |
| Hesdorffer, C | 1 |
| Bernard-Marty, C | 1 |
| Mano, M | 1 |
| Paesmans, M | 1 |
| Accettura, C | 1 |
| Munoz-Bermeo, R | 1 |
| Richard, T | 1 |
| Kleiber, K | 1 |
| Cardoso, F | 1 |
| Lobelle, JP | 1 |
| Larsimont, D | 1 |
| Piccart, MJ | 1 |
| Di Leo, A | 1 |
| FALKSON, G | 1 |
| SNYMAN, HJ | 1 |
| Campone, M | 1 |
| Roché, H | 1 |
| Kerbrat, P | 1 |
| Bonneterre, J | 1 |
| Romestaing, P | 1 |
| Fargeot, P | 1 |
| Namer, M | 1 |
| Monnier, A | 1 |
| Montcuquet, P | 1 |
| Goudier, MJ | 1 |
| Fumoleau, P | 1 |
| Shapiro, S | 1 |
| Hughes, G | 1 |
| Al-Obaidi, MJ | 1 |
| O'Reilly, E | 1 |
| Ramesh, S | 1 |
| Smith, J | 1 |
| Ahmad, R | 1 |
| Dawson, C | 1 |
| Riddle, P | 1 |
| Sekhar, M | 1 |
| Kikuchi, T | 1 |
| Kubonishi, S | 1 |
| Shibakura, M | 1 |
| Namba, N | 1 |
| Matsui, T | 1 |
| Fukui, Y | 1 |
| Tanimoto, M | 1 |
| Katayama, Y | 1 |
| Saito, T | 1 |
| Komada, Y | 1 |
| Zhou, YW | 1 |
| Zhang, XL | 1 |
| Xue, HL | 1 |
| Sakai, H | 1 |
| Tanaka, S | 1 |
| Sakatoku, H | 1 |
| Sakurai, M | 1 |
| Lee, BC | 1 |
| Shav-Tal, Y | 1 |
| Peled, A | 1 |
| Gothelf, Y | 1 |
| Jiang, W | 1 |
| Toledo, J | 1 |
| Ploemacher, RE | 2 |
| Haran-Ghera, N | 1 |
| Zipori, D | 1 |
| Terpstra, W | 1 |
| Prins, A | 1 |
| van Lom, K | 1 |
| Pouwels, K | 1 |
| Wognum, AW | 1 |
| Wagemaker, G | 1 |
| Löwenberg, B | 1 |
| Wielenga, JJ | 1 |
| Lemez, P | 1 |
| Turker, A | 1 |
| Güler, N | 1 |
| Yeh, KH | 1 |
| Yeh, SH | 1 |
| Chang, YS | 1 |
| Cheng, AL | 1 |
| Bergh, J | 1 |
| Wiklund, T | 1 |
| Erikstein, B | 1 |
| Lidbrink, E | 1 |
| Lindman, H | 1 |
| Malmström, P | 1 |
| Kellokumpu-Lehtinen, P | 1 |
| Bengtsson, NO | 1 |
| Söderlund, G | 1 |
| Anker, G | 1 |
| Wist, E | 1 |
| Ottosson, S | 1 |
| Salminen, E | 1 |
| Ljungman, P | 1 |
| Holte, H | 1 |
| Nilsson, J | 1 |
| Blomqvist, C | 1 |
| Wilking, N | 1 |
| Hayashi, M | 1 |
| Okabe, J | 1 |
| Hozumi, M | 1 |
| Reimer, RR | 1 |
| Hoover, R | 1 |
| Fraumeni, JF | 1 |
| Young, RC | 1 |
| Nishiyama, M | 1 |
| Aogi, K | 1 |
| Saeki, S | 1 |
| Hirabayashi, N | 1 |
| Toge, T | 1 |
| Cavaliere, A | 1 |
| Alberti, PF | 1 |
| Vitali, R | 1 |
| Naito, M | 1 |
| Hamada, H | 1 |
| Tsuruo, T | 1 |
| Ishiyama, T | 1 |
| Sugimoto, M | 1 |
| Wakabayashi, Y | 1 |
| Hirose, S | 1 |
| Davis, HL | 1 |
| Prout, MN | 1 |
| McKenna, PJ | 1 |
| Cole, DR | 1 |
| Korbitz, BC | 1 |
| Wilmanns, W | 1 |
| Goldfinger, D | 1 |
| McGinniss, MH | 1 |
| Carey, RW | 1 |
| Holland, JF | 1 |
| Sheehe, PR | 1 |
| Graham, S | 1 |
| Aoki, Y | 1 |
| Moore, GE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Profiling Neutrophil Counts in Patients With Cancer During Cycle One of Chemotherapy[NCT02806557] | 200 participants (Anticipated) | Observational | 2016-09-30 | Not yet recruiting | |||
| A Prospective Randomized Feasibility and Phase II Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors.[NCT00851110] | Phase 2 | 50 participants (Anticipated) | Interventional | 2004-10-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fluorouracil and Leukemia, Myeloid
| Article | Year |
|---|---|
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2005 |
[Current status of cytostatic therapy].
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Cyta | 1974 |
2 trials available for fluorouracil and Leukemia, Myeloid
23 other studies available for fluorouracil and Leukemia, Myeloid
| Article | Year |
|---|---|
The evolution of hematopoietic cells under cancer therapy.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clonal Evolution; C | 2021 |
[High risk of cardiac dysfunction after treatment of secondary acute myeloid leukemia following chemotherapy and radiotherapy for breast cancer].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy | 2010 |
Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, D | 2002 |
Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Belgium; B | 2003 |
EXPERIENCE WITH CHEMOTHERAPY OF CANCER AT THE UNIVERSITY OF PRETORIA.
Topics: Antineoplastic Agents; Aziridines; Breast Neoplasms; Cyclophosphamide; Dactinomycin; Fluorouracil; H | 1964 |
Acute myeloid leukaemia secondary to treatment with capecitabine for metastatic colorectal cancer.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2007 |
Dock2 participates in bone marrow lympho-hematopoiesis.
Topics: Actins; Animals; Bone Marrow; Bone Marrow Transplantation; Chemokine CXCL12; Chemotaxis; Fluorouraci | 2008 |
Fas receptor (CD95)-mediated apoptosis is induced in leukemic cells entering G1B compartment of the cell cycle.
Topics: Acute Disease; Antibodies, Monoclonal; Apoptosis; Cell Division; Child; Child, Preschool; DNA Damage | 1995 |
A hematopoietic organ-specific 49-kD nuclear antigen: predominance in immature normal and tumor granulocytes and detection in hematopoietic precursor cells.
Topics: Acute Disease; Animals; Antigens, Neoplasm; Bone Marrow; Cell Differentiation; Cell Nucleus; Cells, | 1996 |
Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture.
Topics: Acute Disease; Animals; Base Sequence; Chromosomes, Human, Pair 8; DNA Primers; Fluorouracil; Granul | 1996 |
Delayed administration of dexrazoxane provides cardioprotection against anthracyclines in breast cancer or acute myeloid leukemia.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast N | 1997 |
Therapy related acute myeloid leukemia after exposure to 5-fluorouracil: a case report.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Leukemia, Myeloid; Mid | 1999 |
Minimal toxicity to myeloid progenitor cells of weekly 24-hr infusion of high-dose 5-fluorouracil: direct evidence from colony forming unit-granulocyte and monocyte (CFU-GM) clonogenic assay.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Colony-Forming Units Assay; Do | 2000 |
Sensitization of resistant myeloid leukemia clone cells by anti-cancer drugs to factor-stimulating differentiation.
Topics: Antineoplastic Agents; Ascitic Fluid; Cell Differentiation; Cell Line; Clone Cells; Colony-Stimulati | 1979 |
Acute leukemia after alkylating-agent therapy of ovarian cancer.
Topics: Acute Disease; Alkylating Agents; Altretamine; Chlorambucil; Cyclophosphamide; Female; Fluorouracil; | 1977 |
[Combination of a biscoclaurine alkaloid, cepharanthine, and anticancer agents: effects and mechanism in human gastric and pancreatic carcinoma cell lines].
Topics: Alkaloids; Antineoplastic Agents; Benzylisoquinolines; Cell Division; Doxorubicin; Drug Synergism; F | 1991 |
5-Fluorouracil carcinogenesis in BALB/c mice.
Topics: Animals; Carcinogenicity Tests; Female; Fluorouracil; Injections, Intraperitoneal; Leukemia, Lymphoc | 1990 |
ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells.
Topics: Adenosine Triphosphate; Binding Sites; Biological Transport; Camptothecin; Cell Membrane; Dactinomyc | 1988 |
[Chronic myelogenous leukemia following therapy of early gastric cancer].
Topics: Adenocarcinoma; Fluorouracil; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Multiple Prim | 1985 |
Acute leukemia complicating metastatic breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Cyclophosphamide; Female; Fluorouracil | 1973 |
Rh-incompatible platelet transfusions--risks and consequences of sensitizing immunosuppressed patients.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antibodies; Antibody Formation; Blood Group Incompatibili | 1971 |
Association of cancer of the breast and acute myelocytic leukemia.
Topics: Adenocarcinoma; Adult; Aged; Anti-Bacterial Agents; Breast Neoplasms; Carcinoma; Female; Fluorouraci | 1967 |
Comparative sensitivity to various antimetabolites of several established cell lines derived from the buffy coat of normal humans and patients with neoplastic diseases.
Topics: Antimetabolites; Blood Cells; Cell Line; Culture Techniques; Cytarabine; Fluorouracil; Humans; Leuke | 1969 |